Oryzon Genomics Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 46

Employees

  • Stock Symbol
  • ORY

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.08
  • (As of Tuesday Closing)

Oryzon Genomics General Information

Description

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Contact Information

Website
www.oryzon.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
MAD
Corporate Office
  • Sant Ferran 74
  • Cornellà de Llobregat
  • 08940 Barcelona
  • Spain
+34 935 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oryzon Genomics Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.08 $2.12 $1.69 - $2.61 $133M 63.7M 132K -$0.05

Oryzon Genomics Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 116,143 128,225 146,078 134,689
Revenue 0 0 0 0
EBITDA (4,427) (5,554) (7,786)
Net Income (3,095) (3,628) (4,449) (5,541)
Total Assets 116,401 118,167 111,207 107,996
Total Debt 15,130 18,704 15,592
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oryzon Genomics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oryzon Genomics‘s full profile, request access.

Request a free trial

Oryzon Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based the
Biotechnology
Barcelona, Spain
46 As of 2023
00000
000000000 00000

000000

enderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteu
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000

0000 0

oluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occae
0000 000000000
San Diego, CA
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oryzon Genomics Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
aTyr Pharma Formerly VC-backed San Diego, CA 00 00000 00000000 00000
Forge Biologics Formerly VC-backed Grove City, OH 000 00000 000000&0 00000
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA 000 00000 000000&0 00000
You’re viewing 5 of 39 competitors. Get the full list »

Oryzon Genomics Patents

Oryzon Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022254484-A1 Combinations of lsd1 inhibitors for treating myeloid cancers Pending 08-Apr-2021 0000000000
CA-3231846-A1 Combinations of lsd1 inhibitors for treating myeloid cancers Pending 08-Apr-2021 0000000000
EP-4319732-A1 Combinations of lsd1 inhibitors for treating myeloid cancers Pending 08-Apr-2021 0000000000
US-20220288039-A1 Vafidemstat for use in treating autism spectrum disorders Inactive 03-Sep-2019 00000000000
EP-4025210-A1 Vafidemstat for use in treating autism spectrum disorders Pending 03-Sep-2019 A61K31/4245
To view Oryzon Genomics’s complete patent history, request access »

Oryzon Genomics Executive Team (15)

Name Title Board Seat
Enric Rello Director, Operations & Chief Financial Officer
Jordi Xaus Ph.D Chief Scientific Officer
Sonia Gutierrez Chief and Director, Clinical Operations
Emili Torrell Chief Business Development Officer and Director Business Development & Licensing
Neus Virgili Chief Intellectual Property Officer
You’re viewing 5 of 15 executive team members. Get the full list »

Oryzon Genomics Board Members (11)

Name Representing Role Since
Antonio Fornieles Melero Oryzon Genomics Board Member 000 0000
Carlos Buesa Ph.D Self Chairman & Board Member 000 0000
Isabel Aguilera Navarro Self Board Member 000 0000
Tamara Maes Ph.D Oryzon Genomics Deputy Chairman & Board Member 000 0000
You’re viewing 4 of 11 board members. Get the full list »

Oryzon Genomics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oryzon Genomics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Crystax 27-Jan-2009 0000000000 Biotechnology 000000 00
To view Oryzon Genomics’s complete acquisitions history, request access »

Oryzon Genomics ESG

Risk Overview

Risk Rating

Updated April, 10, 2024

26.96 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view Oryzon Genomics’s complete esg history, request access »

Oryzon Genomics FAQs

  • When was Oryzon Genomics founded?

    Oryzon Genomics was founded in 2000.

  • Where is Oryzon Genomics headquartered?

    Oryzon Genomics is headquartered in Barcelona, Spain.

  • What is the size of Oryzon Genomics?

    Oryzon Genomics has 46 total employees.

  • What industry is Oryzon Genomics in?

    Oryzon Genomics’s primary industry is Biotechnology.

  • Is Oryzon Genomics a private or public company?

    Oryzon Genomics is a Public company.

  • What is Oryzon Genomics’s stock symbol?

    The ticker symbol for Oryzon Genomics is ORY.

  • What is the current stock price of Oryzon Genomics?

    As of 23-Jul-2024 the stock price of Oryzon Genomics is $2.08.

  • What is the current market cap of Oryzon Genomics?

    The current market capitalization of Oryzon Genomics is $133M.

  • Who are Oryzon Genomics’s competitors?

    CytomX Therapeutics, aTyr Pharma, Forge Biologics, CRISPR Therapeutics, and Dicerna Pharmaceuticals are some of the 39 competitors of Oryzon Genomics.

  • What is Oryzon Genomics’s annual earnings per share (EPS)?

    Oryzon Genomics’s EPS for 12 months was -$0.05.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »